Advanced Oncotherapy PLC Presentation highlights LIGHT system superiority (3560Q)
27 October 2021 - 5:00PM
UK Regulatory
TIDMAVO
RNS Number : 3560Q
Advanced Oncotherapy PLC
27 October 2021
27 October 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the UK Market Abuse Regulation.
With the publication of this announcement, this information is now
considered to be in the public domain.
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
ASTRO presentation highlights potential superiority of the LIGHT
proton therapy system for the delivery of FLASH radiotherapy
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment, is
pleased to announce that yesterday, Dr Anna-Maria Kolano, Medical
Physicist at Advanced Oncotherapy, made an oral presentation at the
prestigious American Society for Radiation Oncology (ASTRO) 2021
Annual Meeting held in Chicago, USA. Her presentation titled "FLASH
radiotherapy planning with dose rate optimization" provided an
overview of results from an important clinical modelling study
comparing treatment plans for the delivery of proton therapy using
FLASH protocols with the LIGHT system versus legacy proton therapy
systems, suggesting the potential for superior outcomes with the
LIGHT system.
FLASH radiotherapy, in which ultra-high radiation doses, several
orders of magnitude higher than that currently used in conventional
clinical radiotherapy, are delivered in fractions of a second,
offers the potential to treat cancer patients in a single visit,
rather than up to 30 visits with conventional radiation therapy,
and has the potential to revolutionise the future of cancer
treatment(1) . However, to date, most of the studies into FLASH
radiotherapy have used electron beams that have low tissue
penetration, which presents a limitation for translation into
clinical practice. A promising alternate FLASH delivery method is
via proton beam therapy, as the dose can be deposited deeper within
the tissue.
For FLASH radiotherapy to be maximally effective, physicians and
radiation therapists must deliver a uniform radiation dose across
the whole tumour to ensure that even tumours with irregular shapes
are comprehensively irradiated. In principle, proton therapy is
ideally suited to this as a proton beam deposits radiation rapidly
on the Bragg peak spot - the area which will receive the most
radiation and stray radiation (that could damage healthy tissue
outside the contours of the tumour) is minimised. However, in
practice, legacy proton beam systems (cyclotrons) are not designed
to ensure such a fast deposition of the radiation dose: they use
slow-rotating absorbers of high-density materials to physically
vary the depth of the Bragg peak spot in the body and, therefore,
are poorly suited to deliver a conformal and uniform FLASH
radiotherapy treatment. In contrast, the Company's LIGHT system's
proton beam energy is controlled electronically and can move the
Bragg peak up to 200 times per second, enabling it to more
effectively target tumours of all shapes.
The conference presentation at ASTRO detailed two modelled
proton therapy treatment plans prepared for a prostate tumour; one
predicated on the use of a LIGHT system and another predicated on
the use of a legacy cyclotron-based system. Importantly, the data
from the modelling demonstrated that the LIGHT system's design
results in a superior clinical treatment plan enabling, uniquely,
both effective FLASH dose delivery and good conformality of that
dose delivery to the tumour tissue. In contrast, the treatment plan
based on the use of the legacy system could provide either good
conformality of radiation delivery to the tumour tissue, but with
sub-optimal FLASH dose across all the tumour that would be required
for effective treatment, or uniform FLASH irradiation of the tumour
but with poor conformality to the tumour resulting in irradiation
of healthy tissue.
Dr Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy
said:
"There is an urgent need to treat more cancer patients and
reduce the toxicity burden associated with legacy radiation therapy
systems. We believe FLASH is the future of radiation therapy as it
not only promises to improve patient outcomes but also the patient
experience.
"At Advanced Oncotherapy, we are developing our LIGHT proton
therapy system to enable FLASH delivery anywhere in the human body.
The modelled data presented at ASTRO further showcases the LIGHT
system's advantages in comparison to legacy proton therapy systems
in designing FLASH treatment plans, thus enabling tumour targeting
and sparing the surrounding healthy tissues in a reduced number of
patient visits. The ultra-fast energy changes provided by LIGHT
enable us to retain high dose conformality to the cancer target
while delivering low dose rates to the surrounding healthy tissues.
We believe it is this highly differential effect between tumour
killing and healthy tissue protection that makes the FLASH
development so compelling in the context of our LIGHT proton
therapy system."
Notes for editors
1 - Hughes JR, Parsons JL; Int. J. Mol. Sci 21(18): 6492
(2020)
Advanced Oncotherapy plc www.avoplc.com
Dr Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPGUUUUPGPPQ
(END) Dow Jones Newswires
October 27, 2021 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
